Abstract

Coronavirus disease-19 (COVID-19) emerged in late 2019 in China and rapidly became pandemic. As with other coronaviruses, a preponderance of evidence suggests the virus originated in horseshoe bats (Rhinolophus spp.) and may have infected an intermediate host prior to spillover into humans. A significant concern is that SARS-CoV-2 could become established in secondary reservoir hosts outside of Asia. To assess this potential, we challenged deer mice (Peromyscus maniculatus) with SARS-CoV-2 and found robust virus replication in the upper respiratory tract, lungs and intestines, with detectable viral RNA for up to 21 days in oral swabs and 6 days in lungs. Virus entry into the brain also occurred, likely via gustatory-olfactory-trigeminal pathway with eventual compromise to the blood-brain barrier. Despite this, no conspicuous signs of disease were observed, and no deer mice succumbed to infection. Expression of several innate immune response genes were elevated in the lungs, including IFNα, IFNβ, Cxcl10, Oas2, Tbk1 and Pycard. Elevated CD4 and CD8β expression in the lungs was concomitant with Tbx21, IFNγ and IL-21 expression, suggesting a type I inflammatory immune response. Contact transmission occurred from infected to naive deer mice through two passages, showing sustained natural transmission and localization into the olfactory bulb, recapitulating human neuropathology. In the second deer mouse passage, an insertion of 4 amino acids occurred to fixation in the N-terminal domain of the spike protein that is predicted to form a solvent-accessible loop. Subsequent examination of the source virus from BEI Resources determined the mutation was present at very low levels, demonstrating potent purifying selection for the insert during in vivo passage. Collectively, this work has determined that deer mice are a suitable animal model for the study of SARS-CoV-2 respiratory disease and neuropathogenesis, and that they have the potential to serve as secondary reservoir hosts in North America.

Highlights

  • Coronavirus disease-19 (COVID-19) emerged in late 2019 in China and the etiologic agent was identified as a novel betacoronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1,2,3]

  • A significant concern is that SARS-CoV-2 could establish in natural wildlife populations that could lead to transmission events to humans

  • The pathology observed in the respiratory tract resembles that which occurs in human COVID-19 patients, including robust inflammation and infiltration of neutrophils and macrophages, and neurological manifestations in the olfactory bulb and tongue that could impact senses of smell and taste, respectively

Read more

Summary

Introduction

Coronavirus disease-19 (COVID-19) emerged in late 2019 in China and the etiologic agent was identified as a novel betacoronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1,2,3]. Both SARS-CoV and SARS-CoV-2 use angiotensin converting enzyme 2 (ACE2) as a cellular entry receptor in humans [2,4]. The virus likely originated from insectivorous Rhinolophus spp. horseshoe bats Some evidence suggests it may have undergone recombination in the receptor binding domain via an intermediate host prior to its spillover into humans [2,5]. Human ACE2-transgenic mice are susceptible, unlike wildtype laboratory mice [14]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call